Impax Laboratories (IPXL) Tops Q1 EPS by 4c

Impax Laboratories (NASDAQ: IPXL) reported Q1 EPS of $0.43, $0.04 better than the analyst estimate of $0.39. Revenue for the quarter came in at $226 million versus the consensus estimate of $247.2 million.

Impax Laboratories reaffirmed FY2016 guidance.

For earnings history and earnings-related data on Impax Laboratories (IPXL) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Eikon Therapeutics, Inc. (EIKN) Misses Q2 EPS by 163c
• RCM Technologies (RCMT) Tops Q2 EPS by 17c